AI semiconductor company Rebellion (CEO Park Sung-hyun) and medical artificial intelligence (AI) company Lunit (CEO Seo Beom-seok) announced on the 15th that they have signed a memorandum of understanding (MOU) for the advancement of medical AI technology and global business cooperation.
Through this agreement, the two companies plan to build an AI platform optimized for the medical field by combining Runit's medical-specific AI model with Rebellion's AI inference semiconductor (NPU, Neural Processing Unit) and to actively pursue related business development.
Rebellion possesses semiconductor technology for low-power, high-performance AI inference, while Lunit provides medical image-based AI solutions, such as cancer diagnosis and analysis, to 65 countries worldwide. Through this collaboration, the two companies will jointly pursue the commercialization of advanced medical AI technology and the overseas expansion of domestically produced AI solutions.
Specifically, they plan to collaborate on the development of an integrated platform leveraging Lunit's medical AI model and Rebellion's NPU technology, focusing on government projects and public healthcare projects. This will foster synergy across various areas, including improving accessibility, cost efficiency, and operational optimization of medical AI services.
The two companies will also jointly plan and market an appliance-type product that integrates Lunit's medical AI solutions with Rebellion's semiconductors, and pursue expansion into the global market. This strategy aims to address the needs of overseas healthcare sectors, including public health services and national cancer screening programs.
“This collaboration will serve as an opportunity to expand Lunit’s AI technology into a broader industrial ecosystem,” said Seo Beom-seok, CEO of Lunit. “The combination of medical AI models and high-performance NPUs is expected to not only solve practical problems in the medical field, but also contribute to securing competitiveness in the global healthcare market.”
Rebellion CEO Park Sung-hyun said, “Through our two companies’ technological collaboration, we will strengthen the effectiveness and accessibility of domestic medical AI services and create meaningful cases in the global market.”
- See more related articles
You must be logged in to post a comment.